Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Slide 16

<< Previous

Bullboard Posts

Next >>

Post by WalkOverTheStrton Aug 12, 2021 2:52pm

194 Views

Post# 33695221

Slide 16

Slide 16 - refresher on womac

https://secureservercdn.net/72.167.241.46/ln9.cea.myftpupload.com/wp-content/uploads/2021/07/Antibe-Corporate-Presentation-July-2021.pdf

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market